Oncotarget

Clinical Research Papers:

Addition of rapamycin and hydroxychloroquine to metronomic chemotherapy as a second line treatment results in high salvage rates for refractory metastatic solid tumors: a pilot safety and effectiveness analysis in a small patient cohort

Kwan-Hwa Chi, Hui-Ling Ko, Kai-Lin Yang, Cheng-Yen Lee, Mau-Shin Chi and Shang-Jyh Kao _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:16735-16745. https://doi.org/10.18632/oncotarget.3793

Metrics: PDF 1229 views  |   HTML 2133 views  |   ?  


Abstract

Kwan-Hwa Chi1,2, Hui-Ling Ko1, Kai-Lin Yang1, Cheng-Yen Lee1, Mau-Shin Chi1 and Shang-Jyh Kao3

1 Department of Radiation Therapy and Oncology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan

2 School of Medicine and Institute of Biomedical Imaging and Radiological Sciences, National Yang-Ming University, Taipei, Taiwan

3 Division of Chest Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan

Correspondence to:

Kwan-Hwa Chi, email:

Shang-Jyh Kao, email:

Keywords: rapamycin, hydroxychloroquine, metronomic chemotherapy, autophagy

Received: January 15, 2015 Accepted: March 18, 2015 Published: April 12, 2015

Abstract

BACKGROUND:

Autophagy is an important oncotarget that can be modulated during anti-cancer therapy. Enhancing autophagy using chemotherapy and rapamycin (Rapa) treatment and then inhibiting it using hydroxychloroquine (HCQ) could synergistically improve therapy outcome in cancer patients. It is still unclear whether addition of Rapa and HCQ to chemotherapy could be used for reversing drug resistance.

PATIENTS AND METHODS:

Twenty-five stage IV cancer patients were identified. They had no clinical response to first-line metronomic chemotherapy; the patients were salvaged by adding an autophagy inducer (Rapa, 2 mg/day) and an autophagosome inhibitor (HCQ, 400 mg/day) to their current metronomic chemotherapy for at least 3 months. Patients included 4 prostate, 4 bladder, 4 lung, 4 breast, 2 colon, and 3 head and neck cancer patients as well as 4 sarcoma patients.

RESULTS:

Chemotherapy was administered for a total of 137 months. The median duration of chemotherapy cycles per patient was 4 months (95% confidence interval, 3–7 months). The overall response rate to this treatment was of 40%, with an 84% disease control rate. The most frequent and clinically significant toxicities were myelotoxicities. Grade ≥3 leucopenia occurred in 6 patients (24%), grade ≥3 thrombocytopenia in 8 (32%), and anemia in 3 (12%). None of them developed febrile neutropenia. Non-hematologic toxicities were fatigue (total 32%, with 1 patient developing grade 3 fatigue), diarrhea (total 20%, 1 patient developed grade 3 fatigue), reversible grade 3 cardiotoxicity (1 patient), and grade V liver toxicity from hepatitis B reactivation (1 patient).

CONCLUSION:

Our results of Rapa, HCQ and chemotherapy triplet combination suggest autophagy is a promising oncotarget and warrants further investigation in phase II studies.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 3793